Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Vyome Holdings Inc HIND.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended June 30. The lone analyst forecast for the quarter was for a loss of 19 cents per share.
Revenue was $26.96 thousand; analysts expected zero.
Vyome Holdings Inc's reported EPS for the quarter was a loss of 10 cents.
The company reported a quarterly loss of $685.56 thousand.
Vyome Holdings Inc shares had risen by 4.7% this quarter and lost 34.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Vyome Holdings Inc is $11.50, about 80.7% above its last closing price of $2.22
This summary was machine generated from LSEG data August 12 at 09:46 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.19 | -0.10 | Beat |
Mar. 31 2026 | -0.18 | -0.15 | Beat |
Dec. 31 2025 | -0.34 | -0.21 | Beat |
Sep. 30 2025 | -0.11 |
Recent news on Vyome Holdings
See all newsBrief: Vyome - Appoints Jerry Leonard As CFO On August 27, 2026 - SEC Filing
Biopharma firm Vyome Holdings posts Q2 net loss
Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Vyome Holdings Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity